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Abstract
Background—The Advisory Committee on Immunization Practice of Thailand prioritizes 
seasonal influenza vaccinations for populations who are at highest risk for serious complications 
(pregnant women, children 6 months–2 years, persons ≥65 years, persons with chronic diseases, 
obese persons), and health-care personnel and poultry cullers. The Thailand government purchases 
seasonal influenza vaccine for these groups. We assessed vaccination coverage among high-risk 
groups in Thailand from 2010 to 2012.
Methods—National records on persons who received publicly purchased vaccines from 2010 to 
2012 were analyzed by high-risk category. Denominator data from multiple sources were 
compared to calculate coverage. Vaccine coverage was defined as the proportion of individuals in 
each category who received the vaccine. Vaccine wastage was defined as the proportion of 
publicly purchased vaccines that were not used.
Results—From 2010 to 2012, 8.18 million influenza vaccines were publicly purchased (range, 
2.37–3.29 million doses/year), and vaccine purchases increased 39% over these years. Vaccine 
wastage was 9.5%. Approximately 5.7 million (77%) vaccine doses were administered to persons 
≥65 years and persons with chronic diseases, 1.4 million (19%) to healthcare personnel/poultry 
cullers, 82,570 (1.1%) to children 6 months–2 years, 78,885 (1.1%) to obese persons, 26,481 
(0.4%) to mentally disabled persons, and 17,787 (0.2%) to pregnant women. Between 2010 and 
2012, coverage increased among persons with chronic diseases (8.6% versus 14%; p < 0.01) and 
persons ≥65 years (12%, versus 20%; p < 0.01); however, coverage decreased for mentally 
disabled persons (6.1% versus 4.9%; p < 0.01), children 6 months–2 years (2.3% versus 0.9%; p < 
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0.01), pregnant women (1.1% versus 0.9%; p < 0.01), and obese persons (0.2% versus 0.1%; p < 
0.01).
Conclusions—From 2010 to 2012, the availability of publicly purchased vaccines increased. 
While coverage remained low for all target groups, coverage was highest among persons ≥65 
years and persons with chronic diseases. Annual coverage assessments are necessary to promote 
higher coverage among high-risk groups in Thailand.
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1. Introduction
Influenza is an acute, vaccine-preventable infection that annually leads to an estimated 3–5 
million severe illness episodes and approximately 500,000 deaths globally [1,2]. Influenza 
vaccination is the most effective way to prevent influenza virus infection. The World Health 
Organization (WHO) recommends vaccinating those most at risk for serious complications, 
including young children, the elderly, those with chronic illnesses, and pregnant women [2]. 
Vaccination is also recommended for those who easily transmit influenza to high-risk 
populations (i.e., healthcare personnel) [3,4].
Although influenza vaccine is not commonly used in most countries in Southeast Asia, the 
burden of influenza in Southeast Asia is similar to that in other parts of the world where 
influenza vaccine is now routinely used [5–7]. In Thailand from 2005 to 2008, the annual 
incidence of influenza in young children <5 years was 236 per 100,000 and in persons aged 
≥75 was 375 per 100,000 [8].
In Thailand, seasonal vaccination was first used in the public sector in 2004 to vaccinate 
healthcare personnel and poultry cullers in response to avian influenza A (H5N1), and its 
use in pandemic preparedness efforts was articulated in Thailand’s 1st National Strategy 
Plan for Pandemic Influenza Preparedness [9]. Currently, Thailand purchases seasonal 
influenza vaccines which are provided free of charge to four high-risk groups: healthcare 
personnel, poultry cullers, persons aged ≥65 years, and persons with chronic diseases 
[10,11]. Over time Thailand’s Advisory Committee on Immunization Practice (ACIP) has 
expanded influenza vaccine recommendations to include eight high-risk populations (Fig. 1) 
[12,13]. Government purchase of influenza vaccine increased over 350% between 2009 and 
2011 (520,000–2.38 million doses) [14]. Here, we estimate influenza vaccine uptake and 
coverage among high-risk populations in Thailand’s public sector, and assess vaccine 
wastage. These data can be used to evaluate and inform the national vaccination program.
2. Methods
We conducted a retrospective review of seasonal influenza vaccine use in the public sector 
in Thailand from 2010 to 2012. Since this study was evaluating a national program, it was 
exempt from ethical review.
Owusu et al. Page 2
Vaccine. Author manuscript; available in PMC 2015 October 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2.1. Study setting
Thailand is a middle-income country located in Southeast Asia that has a population of 66.0 
million (est. 2010) [15]. The Thai GDP per capita is $5,318USD (est. 2012) [16], and 3.5% 
of Thailand’s GDP is spent on health expenditures (est. 2006) [17]. Thailand can be divided 
into five geographic regions (total est. 2010 population in parentheses): Metropolitan 
Bangkok (8.3 million), North (11.6 million), Northeast (19.0 million), Central (18.2 
million), and South (8.9 million).
2.2. Influenza vaccine distribution
The Thailand National Health Security Office (NHSO) is responsible for providing health 
promotion activities, prevention services, treatment, and rehabilitation services to all who 
are enrolled in the Universal Coverage Scheme [18]. The Universal Coverage Scheme 
provides health insurance to nearly 75% of the Thai population, with the remainder being 
covered under the Social Security Scheme and the Civil Servant Medical Benefits Scheme. 
Following the 2008 recommendation by Thailand’s ACIP to vaccinate persons aged ≥65 
years and persons with chronic diseases, NHSO began purchasing vaccine for these two 
high-risk groups. Vaccines purchased were inactivated, trivalent vaccines, provided to the 
Ministry of Public Health in multi-dose formulation (four doses per vial). Vaccines were 
distributed to each province based on the estimated number of persons in these two target 
groups (some swapping of vaccine between provinces may have occurred). Vaccination was 
administered in provincial and district hospitals during a 3-month campaign (or until vaccine 
ran out) starting in June of each year. In Thailand, outpatient clinics in hospitals serve as 
primary care centers. Healthcare personnel received no additional incentive for providing 
vaccines to the target groups. When administering vaccine, while healthcare providers 
prioritized the two target groups, vaccine was also administered to the other five target 
groups falling under the ACIP recommendation (pregnant women, obese persons weighing 
>100 kg and/or having a body mass index ≥35 kg/m2, mentally disabled persons, and 
children aged 6 months–2 years). Healthcare personnel and poultry cullers also received 
vaccines free of charge, although these were purchased by the Department of Disease 
Control of the Ministry of Public Health. For the purposes of this study, ‘publicly purchased 
vaccines’ refer to those purchased by the Department of Disease Control and NHSO.
2.3. Vaccine database
Each vaccination event was recorded in an electronic health record that was developed by 
NHSO for reimbursement purposes. After each vaccination, hospital staff entered the 
vaccine recipient’s 13-digit unique identification number, date of birth, date of vaccination, 
risk group category, province, and type of health insurance into the electronic health record. 
Patients not covered by the Universal Coverage Scheme could still be vaccinated and 
entered into this system. National data were compiled by NHSO.
2.4. High-risk group classification
In the NHSO electronic database, vaccinees were classified into pre-defined risk groups. 
Each vaccinee was assigned to only one risk category and some risk categories changed over 
time. If a vaccinee fell into >1 risk category, s/he would first be classified in either the 
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chronic disease or aged ≥65 years groups; for the remaining risk categories, classification 
was at the discretion of the health-care provider. Four risk categories were consistent from 
2010 to 2012: obese persons, young children aged 6 months–2 years, mentally disabled 
persons, and pregnant women. Three risk categories changed between 2010 and 2011–2012: 
persons aged ≥65 years, persons with chronic diseases and healthcare personnel/poultry 
cullers. Among the persons aged ≥65 years category, in 2010 all persons aged ≥65 years 
regardless of health status were included, whereas in 2011–2012, persons aged ≥65 years 
with chronic diseases were excluded from the category. In 2010, the persons with chronic 
diseases category excluded persons aged ≥65 years with chronic diseases; however, in 
2011–2012 this category included all persons with chronic diseases regardless of age. 
Finally, the health-care personnel/poultry cullers category included all such workers in 2010, 
while in 2011–2012 poultry cullers/healthcare personnel with chronic diseases were 
excluded from this category.
2.5. Denominator data sources
We used three different data sources to estimate the denominator; coverage for some risk 
group categories was estimated using more than one approach.
2.6. National Statistical Office data
The National Statistical Office reports census data on all registered nationals [19]. We used 
these data to estimate the denominator for persons aged ≥65 years and young children aged 
6 months–2 years. The data were reported in 1-year age increments; to estimate the number 
of infants aged 6 months–1 year, we calculated 50% of the 1-year age category.
2.7. National Health Examination Survey data
The National Health Examination Survey [20] is conducted every five years in Thailand to 
estimate the national prevalence of multiple health conditions. This nationally representative 
survey utilizes multi-stage random sampling to identify 30,000 participants for a health 
interview and examination. The most recent National Heath Examination Survey was 
conducted in 2009. The National Health Examination Survey data were used to estimate the 
denominator for young children aged 6 months–2 years, persons aged ≥65 years, obese 
persons, and for persons with chronic diseases. Chronic diseases included in the survey were 
chronic obstructive pulmonary disorder, asthma, cerebrovascular disease, diabetes mellitus, 
renal failure, and thalassemia.
2.8. NHSO inpatient/outpatient data
NHSO maintains databases of all persons who receive inpatient and/or outpatient care from 
a public hospital in Thailand. All patient visits are coded for reimbursement purposes using 
the 10th Revision of the International Statistical Classification of Diseases and Related 
Health Problems (ICD-10); codes are recorded at the time of final discharge (see 
Supplemental Table S1 for category definitions). Patients could receive up to two final 
diagnosis codes per hospital visit. The data were aggregated, and patients with more than 
one diagnosis were included in each illness category. For each fiscal year (October–
September) that vaccines were purchased, duplicate diagnoses records for the same patient 
Owusu et al. Page 4
Vaccine. Author manuscript; available in PMC 2015 October 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
were deleted. These data were then used to estimate the denominator for persons with 
chronic diseases, pregnant women, obese persons, and mentally disabled persons. Chronic 
diseases included in the survey were heart disease, systemic lupus erythematosus, human 
immunodeficiency virus (HIV), and cancer.
2.9. Statistical analysis
Demographics characteristics (age, sex, and region of residence) of vaccinees are presented 
as number and proportion. All vaccinees were kept in their original NHSO-designated 
categories. However, because some risk group classifications varied by year we also 
combined groups to display all who were classified as persons aged ≥65 years, persons with 
chronic diseases, or healthcare personnel/poultry cullers. Vaccine coverage was calculated 
among the following groups for which we had denominator data: (1) persons aged ≥65 
years; (2) persons with chronic diseases; (3) pregnant women; (4) obese persons; (5) 
mentally disabled persons; and (6) young children aged 6 months–2 years. In addition, we 
aggregated these data to present a total coverage estimate. We used the Wilson score method 
to calculate 95% confidence intervals (CI) for each of our coverage estimates. To graph 
vaccine coverage by year, we used the following denominators for each risk group: National 
Statistical Office census data for young children and persons aged ≥65 years, National 
Health Examination Survey and NHSO data for persons with chronic diseases, National 
Health Examination Survey data for obese persons, and NHSO data for pregnant women and 
persons who were mentally disabled. In the case of calculating coverage for persons with 
chronic diseases, NHSO data were used as the denominator source for conditions not 
included by the National Health Examination Survey: heart disease, immunodeficiency 
conditions (HIV; systemic lupus erythematosus), and cancer. National Health Examination 
Survey data were used as a denominator for chronic obstructive pulmonary disease, asthma, 
cerebrovascular disease, chronic renal failure, diabetes mellitus, and thalassemia. Sex 
differences in coverage within high-risk groups were calculated using Pearsons’ Chi squared 
test. Vaccine wastage for each year was defined as the proportion of vaccines purchased by 
the public sector for distribution to high-risk populations that were not used by these 
populations. We used Chi squared test for trend when looking at changes over the 3-year 
time period (Epi Info version 7.0, Centers for Disease Control and Prevention, Atlanta, GA, 
USA). For all other analyses, we used PASW version 18.0 (IBM, Armonk, NY, USA). A 
two-tailed p value <0.05 was considered statistically significant.
3. Results
From 2010 to 2012, 8.18 million doses of seasonal influenza vaccine were purchased by the 
Royal Thai government (Table 1). The number of vaccines purchased increased by 39% 
from 2.37 million doses in 2010 to 3.29 in 2012, and over the 3 years 91% of all purchased 
vaccines were administered. From 2010 to 2011, vaccine wastage increased (8.4% versus 
10%), but decreased from 2011 to 2012 (10% versus 9.6%). Across all three years, vaccine 
wastage increased (trend p < 0.01), and was 9.5% per year, on average. Wastage was highest 
in Bangkok (42% in 2010, 26% in 2011, and 17% in 2012).
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3.1. Characteristics of vaccinees
Of all vaccines that were distributed from 2010 to 2012, 29% was administered in 2010, 
31% in 2011, and 40% in 2012 (Table 2). Sixty-five percent of the vaccines was 
administered to females and the median age of all vaccinees was 54 years in 2010, 58 years 
in 2011, and 59 years in 2012. The median age for persons with chronic diseases was 52 
years in 2010 and 57 years in both 2011 and 2012. Across all three years, 765,984 (19%) of 
all persons with chronic diseases who were given a vaccine were aged ≥65 years. Among 
persons classified as persons aged ≥65 years, the median age was 72 years for all three 
years, and 2,550 (0.2%) were 60–64 years (these persons were excluded from the coverage 
estimates below). Among persons classified as young children aged 6 months–2 years, 693 
(0.2%) were aged ≥3 years, and these persons were also excluded from coverage estimates. 
Of the 5 regions in Thailand, the Northeastern region administered the most vaccines 
(2,533,674; 34%), while Bangkok administered the least of the publicly purchased vaccines 
(384,560; 5.2%).
3.2. Vaccinees by target groups
From 2010 to 2012, 77% of vaccines were distributed to two target groups: 3,974,848 (54%) 
doses were administered to persons with chronic diseases and 1,721,490 (23%) to persons 
aged ≥65 years persons (Table 3). Additionally, 1,426,686 (19%) vaccines were 
administered to healthcare personnel and poultry cullers, 82,570 (1.1%) to young children 
aged 6 months–2 years, 78,885 (1.1%) to obese persons, 78,516 (1.1%) to persons whose 
risk group was listed as other (not specified), 26,481 (0.4%) to mentally disabled persons, 
and 17,787 (0.2%) to pregnant women. The proportion of vaccines administered to persons 
with chronic diseases increased from 2010 to 2011, and increased in persons aged ≥65 years 
from 2011 to 2012. When the two groups were combined to control for coding changes, 
there was only a decrease from 2011 to 2012. The proportion of vaccines that were 
administered to all other risk groups decreased from 2010 to 2012 (Table 3).
3.3. Influenza vaccine coverage
Excluding healthcare personnel, poultry cullers, and those who were missing a risk group 
classification, overall coverage for the combined risk groups was 4.5% in 2010, 4.9% in 
2011, and 6.3% in 2012 (Fig. 2). For all three years combined, coverage estimates for 
persons with chronic diseases ranged from 12% using the National Heath Examination 
Survey denominator to 30% using NHSO data. Among persons aged ≥65 years, coverage 
ranged from 14% using National Heath Examination Survey data to 15% using National 
Statistical Office data. Coverage estimates among obese persons ranged from 0.1% using 
National Heath Examination Survey data to 41% using NHSO data. Coverage estimates 
ranged from 0.8% to 0.9% in pregnant women and 1.5% to 1.6% in young children aged 6 
months–2 years. Coverage among persons with mental disabilities was 4.9%.
From 2010 to 2012, vaccine coverage increased in persons with chronic diseases (8.6%, 
11.2%, and 13.9%, respectively; p < 0.01), and persons aged ≥65 years (11.5%, 14.3%, and 
19.6%, respectively; p < 0.01; see Table 4 and Fig. 2). Combined vaccine coverage for 
persons with chronic diseases and persons aged ≥65 years was 9.5% in 2010, 12.2% in 2011, 
and 15.7% in 2012. In all other target groups, vaccine coverage decreased between 2010 and 
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2012: 2.3–0.9% in young children aged 6 months–2 years (p < 0.01), 0.2–0.1% in obese 
persons (p < 0.01), 6.1% versus 4.9% in mentally disabled persons (p < 0.01), and 1.1–0.9% 
in pregnant women (p < 0.01).
Coverage was higher among males than females among young children (male: 1.5%, 
female: 1.4%, p < 0.01), and mentally disabled persons (male: 8.0%, female: 5.8%, p < 
0.01). In contrast, coverage was higher among females than males among obese persons 
(0.15% versus 0.13%, p < 0.01), persons aged ≥65 years (12.9% versus 11.1%, p < 0.01) and 
persons with chronic diseases (16.6% versus 9.6%, p < 0.01).
4. Discussion
This is the first vaccine coverage evaluation of the influenza vaccine program in Thailand. 
We found that the number of publicly purchased influenza vaccines increased 39% from 
2010 to 2012, yet vaccine wastage also increased and averaged 9.5% annually. Overall 
vaccine coverage (excluding healthcare personnel and poultry cullers for which we had no 
denominator) was low (6.3% in 2012), but was highest (16% in 2012) in the two priority 
risk groups, persons with chronic diseases, and persons aged ≥65 years. Additionally, 
coverage increased among these groups from 2010 to 2012; however, in all other high-risk 
groups, coverage decreased. Use of different denominators generally had only a small effect 
on coverage estimates except among obese persons. We hypothesize that few persons are 
given an admission diagnosis of obesity thus underestimating the NHSO denominator.
The distribution of publicly purchased influenza vaccine to high-risk groups is a relatively 
new initiative in Thailand. Although vaccination of healthcare personnel and poultry cullers 
began in 2004, it was not until 2008 that Thailand’s NHSO began to purchase seasonal 
vaccines for persons aged ≥65 years and persons with chronic diseases. During the 2009 
influenza pandemic, national influenza vaccine recommendations were expanded to include 
additional high-risk populations: pregnant women, young children aged 6 months–2 years, 
obese persons, and mentally disabled persons. However, persons aged ≥65 years and persons 
with chronic diseases have remained the priority groups for the influenza vaccine plan of the 
national health coverage scheme. This explains the relatively higher coverage in these two 
risk groups.
While influenza vaccination is increasing globally [21], coverage among high-risk groups 
varies between countries. One study on vaccine coverage in Germany, Spain, Italy, the 
United Kingdom, and France, estimated that during the 2006/2007 influenza season, vaccine 
coverage among persons aged ≥65 years and persons with chronic diseases ranged from 
50% to 70% and 30% to 59%, respectively [22]. In the United States, vaccine coverage was 
estimated to be 77% (2012/2013) among children aged 6–23 months, 66% (2012/2013) 
among persons aged ≥65 years, and 43% (2011/2012) among pregnant women [23,24]. 
Higher coverage in the United States and Europe than in Thailand may reflect the maturity 
of these programs; for instance, the U.S. ACIP began making influenza vaccine 
recommendations for high-risk groups in 1984, whereas the Thai ACIP only began making 
recommendations in 2004. In South Korea, a country that in recent years has increased its 
vaccine purchases, vaccine coverage was estimated at 61% among persons aged ≥65 years 
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and persons with chronic diseases, during the 2004/2005 influenza season. However, 17 
million vaccines were available during the 2004/2005 influenza season, and 33% of the total 
population in South Korea received vaccine [25].
A major strength of our evaluation was our ability to use a national dataset on vaccine status 
for all individuals who received vaccines from public hospitals in Thailand. However, our 
evaluation also had several limitations. First, vaccine records were not standardized across 
all three years which resulted in changes in risk group classification between years making it 
difficult to assess temporal changes in coverage. For this reason, the coverage for combined 
risk groups is more likely to be accurate. Second, vaccines distributed to healthcare 
personnel and poultry cullers were pooled in the dataset, making it impossible to ascertain 
vaccine coverage in healthcare personnel separately, an important risk group. Third, there 
was no ideal denominator data source for persons with underlying disease and since some 
persons may have more than one underlying disease and therefore counted multiple times, 
we may have underestimated coverage. Fourth, since vaccinees could only be classified in 
one risk group, we may have underestimated coverage for some risk groups. Fifth, we did 
not have access to information on vaccines that went to a person not defined as a high-risk 
group (e.g., military personnel or prisoners) so the estimates of wastage are likely 
overestimated; despite this, wastage rates were as expected for multi-dose vials [26]. Finally, 
we did not include data on privately purchased influenza vaccine, which were about 1.5 
times public sales in 2011 [14]. Therefore, we likely underestimate coverage estimates.
As Thailand continues to increase the use of influenza vaccine, these findings are important 
to establish baseline coverage and highlight programmatic challenges that can be addressed 
to increase coverage and reduce wastage. We hypothesize that optimal vaccine use can be 
achieved through better outreach to targeted population; however, future studies are needed 
to investigate acceptance and barriers to influenza vaccine receipt among high-risk groups in 
Thailand, as well as specific reasons for wastage, particularly in Bangkok (e.g., cold chain 
barriers or suboptimal outreach). Annual estimates of vaccine coverage will be important to 
assess progress toward program goals. Further, an existing effective influenza vaccine 
program is critical in the event of a pandemic where rapid vaccine deployment and 
assessment is paramount. The results of this evaluation will inform future evaluation of 
influenza vaccine coverage and management in Thailand.
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Fig. 1. 
ACIP-recommended influenza vaccination target groups in Thailand by year of 
recommendation.
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Fig. 2. 
Vaccine coverage by year and target group, Thailand 2010–2012. We do not include 
coverage rates for healthcare personnel, poultry cullers, and those who were missing a risk 
group classification as we do not have denominator data for these risk groups.
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Table 1
Number of influenza vaccine doses that were publicly purchased and used by year in Thailand, 2010–2012.
Year Vaccines purchased Vaccines used, N(%) Vaccines wasted (%)
2010 2,370,678 2,170,813 (92) 8.4
2011 2,515,880 2,259,614 (90) 10
2012 3,294,000 2,976,836 (90) 9.6
Total 8,180,558 7,407,263 (91) 9.5
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Table 2
Descriptive characteristics of population receiving influenza vaccinea in the public sector in Thailand, 2010–
2012.
Characteristic Total (n = 7,407,263) 2010 (n = 2,170,813) 2011 (n = 2,259,614) 2012 (n = 2,976,836)
Sex, male, n (%) 2,581,454 (35) 765,585 (35) 778,543 (35) 1,037,326 (35)
Age, mean ± SD (median)
All vaccinees 54 ± 19 (57) 51 ± 20 (54) 55 ± 18 (58) 56 ± 18 (59)
 Chronic disease 53 ± 17 (56) 47 ± 16 (52) 54 ± 17 (57) 55 ± 16 (57)
 Persons aged >65 years 73 ± 6 (72) 73 ± 6 (72) 73 ± 6 (72) 73 ± 6 (72)
 Pregnant women 27 ± 8 (26) 27 ± 7 (26) 27 ± 8 (26) 27 ± 8 (26)
 Obese 41 ± 16 (43) 41 ± 15 (43) 42 ± 16 (45) 41 ± 16 (43)
 Mentally disabled 33 ± 21 (30) 33 ± 21 (30) 34 ± 21 (31) 32 ± 21 (28)
 Young children (age 6 months–2 years) 2 ± 5 (1.0) 2 ± 6 (1.0) 1 ± 1 (1.0) 1 ± 1 (1.0)
 Other 46 ± 17 (49) N/A 57 ± 4 (40) 46 ± 17 (42)
Place of residence, n (%)
Northeastern region 2,533,674 (34) 728,231 (34) 774,554 (34) 1,030,889 (35)
 Bangkok 384,560 (5.2) 121,003 (5.6) 117,330 (5.2) 146,227 (4.9)
 Central region 1,790,625 (24) 520,924 (24) 55,0518 (24) 719,183 (24)
 Southern region 978,684 (13) 303,304 (14) 293,449 (13) 381,931 (13)
 Northern region 1,718,443 (23) 497,004 (23) 523,342 (23) 698,097 (23)
a
Data missing on 922 (0.01%) for sex, 1,569 (0.02%) for age, and 1,277 (0.02%) for place of residence.
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Table 3
Number of influenza vaccines administered by target group and year, Thailand 2010–2012.
Target group Number of vaccine doses distributed
2010 N (%) 2011 N (%) 2012 N (%) Total N (%)
Chronic disease Aged <65 yearsa Alla 1,006,960 (46) 1,324,662 (59) 1,643,226 (55) 3,974,848 (54)
1,006,960 – –
– 1,324,662 1,643,226
Age ≥65 years 576,035 (27) 454,101 (20) 691,354 (23) 1,721,490 (23)
 Alla 576,035 – –
 No chronic diseasea – 454,101 691,354
Chronic disease and age ≥65 years combined 1,582,995 (73) 1,778,763 (79) 2,334,580 (78) 5,696,338 (77)
Healthcare personnel/poultry cullers 487,953 (23) 424,403 (19) 514,330 (17) 1,426,686 (19)
 Alla 487,953 – –
 No chronic diseasea – 424,403 514,330
Young children (aged 6 months–2 years)a 43,860 (2.0) 21,989 (1.0) 16,721 (0.6) 82,570 (1.1)
Obesea 37,995 (1.8) 21,701 (1.0) 19,189 (0.7) 78,885 (1.1)
Othera – 2 78,514 (2.6) 78,516 (1.1)
Mentally disableda 10,489 (0.5) 7,884 (0.4) 8,108 (0.3) 26,481 (0.4)
Pregnant womena 7,521 (0.4) 4,872 (0.2) 5,394 (0.2) 17,787 (0.2)
a
Denotes NHSO categorization for the risk groups.
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